{"url_path":"/sec/asbpw/8-k/2026-05-14/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1847345/0001493152-26-023069-index.html","accession_number":"0001493152-26-023069","cik":"0001847345","ticker":"ASBP","issuer_name":"Aspire Biopharma Holdings, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1847345/0001493152-26-023069-index.html","primary_entity_key":"0001847345","primary_entity_name":"Aspire Biopharma Holdings, Inc."},"word_count":98,"has_tables":true,"body_markdown":"**Item\n9.01 Financial Statements and Exhibits.**\n\n \n\n**Exhibit\nNumber**\n \n**Description**\n\n3.1\n \n[Certificate of Amendment to the Certificate of Incorporation of Aspire Biopharma Holdings, Inc., filed with the Secretary of State of the State of Delaware on May 11, 2026](ex3-1.htm)\n\n104\n \nCover\nPage Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n \n\n \n\n \n\n**SIGNATURE**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\n \n**ASPIRE\nBIOPHARMA HOLDINGS, INC.**\n\n \n \n \n\n \nBy:\n*/s/\nErnest Scheidemann*\n\n \n \nErnest\nScheidemann\n\n \n \nChief\nFinancial Officer\n\n \n \n \n\nDate:\nMay 14, 2026"}